Acta Diabetologica

, Volume 47, Supplement 1, pp 35–46

Beneficial effects of astragalus polysaccharides treatment on cardiac chymase activities and cardiomyopathy in diabetic hamsters

  • Wei Chen
  • Mao-Hua Yu
  • Yi-Ming Li
  • Wen-Jie Chen
  • Yian-Ping Xia
Original Article

Abstract

Over-activation of the local chymase–angiotensin II (Ang II) system has a dominant role in diabetic cardiomyopathy. Astragalus polysaccharides (APS) are used in traditional Chinese medicine to boost immunity. In this study, we investigated the effects of APS treatment on cardiac function, myocardial collagen expression, cardiac ultrastructure, cardiac matrix metalloproteinase (MMP) activity, levels of plasma glycosylated serum protein (GSP), and myocardial enzymes, and the expression of Ang II, chymase, and angiotensin-converting enzyme (ACE) in the diabetic hamster myocardium. Diabetes was induced by a single injection of streptozotocin (60 mg/kg ip). The experimental groups consisted of normal control (n = 15), diabetic (n = 15), insulin-treated diabetic (n = 15, NPH 1–2 U/day ip), and APS-treated diabetic (n = 30, APS 1–2 g/kg/day orally for 10 weeks) hamsters. Diabetic hamsters treated with insulin or APS exhibited significantly decreased blood glucose, plasma GSP, and myocardial enzymes, as well as improvements in cardiac function and cardiac ultrastructure. Compared with insulin treatment, APS treatment significantly reduced myocardial collagen (type I and III) expression and lowered cardiac MMP-2 activity, myocardial Ang II levels, myocardial chymase expression, and p-ERK1/2 kinase expression. In diabetic hamsters, myocardial ACE expression and plasma Ang II levels was not altered by insulin or APS treatment. These results indicate that treatment of diabetic hamsters with APS inhibited the local chymase–Ang II system and improved markers of diabetic cardiomyopathy.

Keywords

Astragalus polysaccharides Diabetes Cardiomyopathy Chymase Angiotensin II 

References

  1. 1.
    Flack JM, Hamaty M, Staffilen BA (2004) Renin-angiotensin-aldosterone-kinin system influences on diabetic vascular disease and cardiomyopathy. Miner-Electrolyte Metab 24(6):412–422CrossRefGoogle Scholar
  2. 2.
    Urata H, Kinoshita A, Misono KS (2000) Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 265(36):22348–22359Google Scholar
  3. 3.
    Nishimoto M, Takai S, Sawada Y (2001) Chymase-dependent angiotensin II formation in the saphenous vein versus the internal thoracic artery. J Thorac Cardiovasc Surg 121(4):729–736CrossRefPubMedGoogle Scholar
  4. 4.
    Ni Y, Su Q, Liu X (1998) Experimental study of optimized techniques of water decoction extraction of Astragalus polysaccharide. China J Chin Med 23(6):284–286Google Scholar
  5. 5.
    Chen W, Yu M-H (2004) Effects of astragalus polysaccharide on gene expression profiles in islets of NOD mice with microarray technique. Chin J Endocrinol Metab 20(6):545–548Google Scholar
  6. 6.
    Chen W, Yu M-H, Li Y-M (2007) Effects of astragalus polysaccharides on ultrastructure and oxidation/apoptosis related cytokines’ gene expression of NOD mice’s islets. Fudan Univ J Med Sci 34(2):269–272Google Scholar
  7. 7.
    Chen W, Xia Y-P, Yu M-H (2007) Astragalus polysaccharides effect on pancreatic histopathology. China J Modern Med 17(2):146–148Google Scholar
  8. 8.
    Chen W, Li Y-M, Yu M-H (2007) Immunoregulation effects of astragalus polysaccharides on T helper lymphocyte subgroups in nonobese diabetic mice. China J Modern Med 17(1):28–31Google Scholar
  9. 9.
    Cong L, Li Y-M, Yu M-H (2006) Effect of astragalus polysaccharides on the expression of myocardial collagen in hamsters with diabetic cardiomyopathy. Chin J Clin Rehab 10(7):64–66Google Scholar
  10. 10.
    Sunni S, Bishop SP, Kent SP (2001) Diabetic cardiomyopathy, a morphological study of intramyocardial arteries. Arch Pathol Lab Med 110(5):375–389Google Scholar
  11. 11.
    Takai S, Sakaguchi M, Jin DL (2001) Different angiotensin II-forming pathways in human and rat vascular tissues. Clin Chim Acta 305(1–2):191–203CrossRefPubMedGoogle Scholar
  12. 12.
    Packer M, Poole-Wilson PA, Armstrong PW (1999) Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100(23):2312–2322PubMedGoogle Scholar
  13. 13.
    Uchiyama-Tanaka Y, Matsubara H, Nozawa Y (2001) Angiotensin II signaling and HB-EGF shedding via metalloproteinase in glomerular mesangial cells. Kidney Int 60(6):2153–2161CrossRefPubMedGoogle Scholar
  14. 14.
    Sekine S, Nitta K, Uchida K (2003) Possible involvement of mitogen-activated protein kinase in the angiotensin II-induced fibronectin synthesis in renal interstitial fibroblasts. Arch Biochem Biophys 415(1):63–77CrossRefPubMedGoogle Scholar
  15. 15.
    Awazu M, Ishikura K, Hida ML (1999) Mechanisms of mitogen-activated protein kinase activation in experimental diabetes. J Am Soc Nephrol 10(4):738–744PubMedGoogle Scholar
  16. 16.
    Takai S, Miyazaki M (2002) The role of chymase in vascular proliferation. Drug News Perspect 15(5):278–285CrossRefPubMedGoogle Scholar
  17. 17.
    Jin D, Takai S, Yamada M (2000) The functional ratio of chymase and angiotensin converting enzyme in angiotensin I-induced vascular contraction in monkeys, dogs and rats. Jpn J Pharmacol 84(4):449–455CrossRefPubMedGoogle Scholar
  18. 18.
    Jin D, Takai S, Yamada M (2001) Possible roles of cardiac chymase after myocardial infarction in hamster hearts. Jpn J Pharmacol 86(2):203–208CrossRefPubMedGoogle Scholar
  19. 19.
    Miyazaki M, Takai S (2001) Local angiotensin II-generating system in vascular tissues: the roles of chymase. Hypertens Res 24(3):189–194CrossRefPubMedGoogle Scholar
  20. 20.
    Yu CM, Tipoe GL, Wing-Hon Lai K (2001) Effects of combination of angiotensin converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction. J Am Coll Cardiol 38(4):1207–1211CrossRefPubMedGoogle Scholar
  21. 21.
    Frank BT, Rossall JC, Caughey GH (2001) Mast cell tissue inhibitor of metalloproteinase-1 is cleaved and inactivated extracellularly by alpha-chymase. J Immunol 166(4):2783–2793PubMedGoogle Scholar
  22. 22.
    Browe GL, Chancey AL, Thanigaraj S (2002) Cause and effect relationship between myocardial mast cell number and matrix metalloproteinase activity. Am J Physiol Heart Circ Physiol 283(2):H518–H523Google Scholar
  23. 23.
    de Almeida A, Mustin D, Forman MF (2002) Effects of mast cells on the behavior of isolated heart fibroblasts: modulation of collagen remodeling and gene expression. J Cell Physiol 191(1):51–62CrossRefPubMedGoogle Scholar
  24. 24.
    Hara M, Ono K, Hwang MW (2002) Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med 195(3):375–381CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Wei Chen
    • 1
  • Mao-Hua Yu
    • 1
  • Yi-Ming Li
    • 2
  • Wen-Jie Chen
    • 1
  • Yian-Ping Xia
    • 1
  1. 1.Department of GeriatricsHuashan Hospital, Fudan University School of MedicineShanghaiChina
  2. 2.Department of EndocrinologyHuashan Hospital, Fudan University School of MedicineShanghaiChina

Personalised recommendations